EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
The plan to file Lentiglobin for sickle cell disease next year gets the green light, as a patient death is deemed unrelated to treatment.
Asco 2020 movers – cell therapy companies dominate the risers
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Asco 2020 – abstract dump triggers first moves
An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.
Another knock for the Celgene contingent value right
A week after one Bristol-Myers Squibb approval decision was delayed a second suffers a similar fate, and the group’s CVR slowly unravels.
Covid-19 adds a new danger to drug launches
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
Holding a contingent value right in uncertain times
Though the stage is apparently set for Bristol’s contingent value right to pay out, the instrument trades at depressed levels.
Biotech’s balancing act amid Covid-19 delays
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Plenty of choice remains for buyers of gene therapy
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Glaxo’s myeloma Dreamm turns into a nightmare
Belantamab’s registrational Dreamm-2 study comes up short of an earlier trial and, more importantly, now seriously lags competitors’ data.
